Company intelligence / Profile preview

Singulex

Alameda/Hayward, California, United Statessingulex.com ↗

Ownership: Private
Development stage: Commercial

Overview

Singulex developed and commercialized ultra-sensitive immunodiagnostic platforms using proprietary Single Molecule Counting technology. Its Sgx Clarity® system enabled detection of cardiac troponin I at unprecedented sensitivity for cardiovascular risk assessment and diagnosis. The company’s products were CE-marked and available in Europe but not cleared for sale in the U.S.; it filed a FDA pre-market notification in late-stage operations before ceasing business.

Therapeutic areas: CardiovascularImmunologyInfectious Diseases
Modalities: DeviceImmunoassay (as a diagnostic platform)Protein detection technology
Industry: Protein Biomarker Diagnostics

Partnerships

Research institutions and custom assay partnerships

Beyond the preview

Go deeper on Singulex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Singulex.

Explore the full profile